Ocrevus (ocrelizumab) / Biogen, Roche 
Welcome,         Profile    Billing    Logout  

81 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ocrevus (ocrelizumab) / Roche
2018-000780-91: STUDY TO ASSESS OCRELIZUMAB EFFICACY, SAFETY AND IMPACT ON PATIENT REPORTED OUTCOMES (PROS) IN PATIENTS WITH ACTIVE RELAPSING MULTIPLE SCLEROSIS (PRO-MSACTIVE)

Not yet recruiting
4
570
Europe
Ocrelizumab, RO4964913, Concentrate for solution for infusion, Ocrevus 300 mg, solution à diluer pour perfusion
ROCHE, ROCHE SAS
ACTIVE RELAPSING MULTIPLE SCLEROSIS (Active RMS), ACTIVE RMS is an autoimmune disease that causes inflammation of theinsulating membranes (myelin) that surround nerves within the centralnervous system., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04650321: Home Based Infusions for Ocrelizumab

Recruiting
4
110
US
Ocrelizumab at home
University of Colorado, Denver, Genentech, Inc.
Multiple Sclerosis
08/21
08/21
2021-000062-14: A Study to Evaluate B Cell Levels in Infants Potentially Exposed to Ocrelizumab During Pregnancy Estudio para Evaluar la Concentración de Linfocitos B En Niños Potencialmente Expuestos al Ocrelizumab Durante el embarazo

Not yet recruiting
4
44
Europe
Concentrate for solution for infusion, Ocrevus
F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications] Esclerosis múltiple (EM) o síndrome clínico aislado (SCA) en consonancia con las indicaciones autorizadas en el país, MS is a chronic disease in which the immune system attacks the insulation and support around the nerve cells in the brain, spinal cord and optic nerves, causing inflammation and consequent damage. EM: enf crónica en q el sistema inmunológico ataca el aislamiento y el soporte alrededor de células nerviosas del cerebro, médula espinal y nervios ópticos, provocando inflamación y consiguiente daño, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04230174: Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation

Not yet recruiting
4
24
NA
11C-PBR28
Massachusetts General Hospital, Genentech, Inc.
Multiple Sclerosis
01/22
07/22
2021-004791-34: Personalized dosing of ocrelizumab in MS

Ongoing
4
296
Europe
ocrelizumab, Solution for infusion, Ocrevus
VU medical center, ZonMw
Multiple sclerosis, MS, Diseases [C] - Nervous System Diseases [C10]
 
 
2021-003296-33: OPEN-LABEL MULTICENTER STUDY TO DETERMINE THE EFFECT OF OCRELIZUMAB ON LEPTOMENINGEAL INFLAMMATION IN MULTIPLE SCLEROSIS (LEGATO)

Not yet recruiting
4
50
Europe
OCRELIZUMAB, RO4964913, Solution for infusion, OCREVUS
F. Hoffmann-La Roche Ltd., F. Hoffmann-La Roche Ltd.
Active progressive multiple sclerosis, Patients of both genders with active progressive multiple sclerosis, defined with Lublin 2013 classification, Diseases [C] - Nervous System Diseases [C10]
 
 
CHIMES, NCT04377555: Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.

Active, not recruiting
4
179
US, RoW
Ocrelizumab
Genentech, Inc.
Multiple Sclerosis, Relapsing
12/25
12/25
CELLO, NCT04877457: Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.

Terminated
4
3
US
Ocrelizumab, Placebo
Yale University, Genentech, Inc.
Radiologically Isolated Syndrome, Multiple Sclerosis
06/23
06/23
NCT04387734: Effects of Ocrevus in Relapsing Multiple Sclerosis

Active, not recruiting
4
60
US
Ocrelizumab, Ocrevus, Platform, Other injectable Disease Modification Treatments
Georgia State University, Multiple Sclerosis Center of Atlanta
Relapsing Multiple Sclerosis
01/25
09/25
SOPRANINO, NCT04998851 / 2021-000063-79: A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

Active, not recruiting
4
20
Europe, US
Ocrelizumab
Hoffmann-La Roche, PPD, Laboratory Corporation of America, Illingworth Research Group
Multiple Sclerosis, Clinically Isolated Syndrome
03/24
02/25
NCT04261790: Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

Active, not recruiting
4
10
US
Ocrelizumab, Ocrevus
Johns Hopkins University, Genentech, Inc.
Multiple Sclerosis, Relapsing-Remitting
12/24
07/25
MINORE, NCT04998812: A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

Active, not recruiting
4
44
Europe, US
Ocrelizumab
Hoffmann-La Roche, PPD, Laboratory Corporation of America, Illingworth Research Group
Multiple Sclerosis, Clinically Isolated Syndrome
04/24
04/25
NCT03853746: Short-term B-cell Depletion in Relapsing Multiple Sclerosis

Active, not recruiting
4
10
US
Ocrelizumab, Ocrevus
Johns Hopkins University, National Multiple Sclerosis Society
Multiple Sclerosis
03/24
07/24
BLOOMS, NCT05296161: B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis

Recruiting
4
296
Europe
Ocrelizumab, ocrevus
Amsterdam UMC, location VUmc
Multiple Sclerosis, Relapsing-Remitting
04/24
03/26
LEGATO, NCT05208840: A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis

Withdrawn
4
50
RoW
Ocrelizumab, RO4964913
Hoffmann-La Roche
Multiple Sclerosis
01/25
01/26
IMPACT MS, NCT04466150: Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Active, not recruiting
4
30
US
Ocrelizumab, Ocrevus
University of California, San Francisco, Genentech, Inc., Valhalla Foundation
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
12/26
07/27
NCT05285891: Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Recruiting
4
175
US
Ocrelizumab, Ocrevus, Placebo for Ocrelizumab
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence (ACE), Rho Federal Systems Division, Inc., Genentech, Inc.
Multiple Sclerosis
08/28
08/28
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
04/30
09/30
OPERA I, NCT01247324 / 2010-020337-99: A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Checkmark CMSC 2016: OPERA I and OPERA II
Jun 2016 - Jun 2016: CMSC 2016: OPERA I and OPERA II
Checkmark AAN 2016: OPERA I & OPERA II
Mar 2016 - Mar 2016: AAN 2016: OPERA I & OPERA II
Checkmark ACTRIMS Forum 2016: Multiple sclerosis (OPERA I & OPERA II)
More
Completed
3
821
Europe, US, RoW
Interferon beta-1a, Rebif, Ocrelizumab-matching placebo, Ocrelizumab, RO4964913, Interferon beta-1a-matching placebo
Hoffmann-La Roche
Relapsing Multiple Sclerosis
04/15
12/22
OPERA II, NCT01412333 / 2010-020315-36: A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Checkmark CMSC 2016: OPERA I and OPERA II
Jun 2016 - Jun 2016: CMSC 2016: OPERA I and OPERA II
Checkmark AAN 2016: OPERA I & OPERA II
Mar 2016 - Mar 2016: AAN 2016: OPERA I & OPERA II
Checkmark ACTRIMS Forum 2016: Multiple sclerosis (OPERA I & OPERA II)
More
Completed
3
835
Europe, Canada, US, RoW
Interferon beta-1a, Rebif, Ocrelizumab-matching placebo, Ocrelizumab, RO4964913, Interferon beta-1a-matching placebo
Hoffmann-La Roche
Relapsing Multiple Sclerosis
05/15
12/22
ORATORIO, NCT01194570 / 2010-020338-25: A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Checkmark CMSC 2016; ORATORIO
Jun 2016 - Jun 2016: CMSC 2016; ORATORIO
Checkmark ACTRIMS Forum 2016: Multiple sclerosis ( ORATORIO )
Feb 2016 - Feb 2016: ACTRIMS Forum 2016: Multiple sclerosis ( ORATORIO )
Checkmark From ORATORIO trial for primary progressive multiple sclerosis at ECTRIMS 2015
More
Completed
3
735
Europe, Canada, US, RoW
Ocrelizumab, Placebo
Hoffmann-La Roche
Multiple Sclerosis, Primary Progressive
07/15
12/22
2017-004158-40: NA NA

Not yet recruiting
3
71
Europe
Ocrevus, Concentrate for solution for infusion
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), ROCHE
Patients with Relapsing MS or primary progressive MS Patients atteints de SEP récurrente (RMS) ou de SEP progressive primaire (PPMS), Multiple Sclerosis Sclérose en Plaque, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-001205-23: Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease

Not yet recruiting
3
211
Europe
Ocrelizumab, Rituximab, Concentrate for solution for infusion, Ocrevus, Rituximab
Helse Bergen HF, Haukeland University Hospital, Program for klinisk behandlingsforskning i spesialisthelsetjenesten (KLINBEFORSK)
Remitting Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-002981-15: Non-inferiority study of ocrelizumab and rituximab in active multiple sclerosis.

Not yet recruiting
3
594
Europe
Concentrate for solution for infusion, Ocrevus, Ruxience
Danish Multiple Sclerosis Center, Rigshospitalet, Danish Regions
Multiple sclerosis., Multiple sclerosis., Diseases [C] - Nervous System Diseases [C10]
 
 
2021-006107-15: LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS: CONSONANCE EXTENSION STUDY

Not yet recruiting
3
90
Europe
Ocrelizumab, RO4964913, Concentrate for solution for infusion, OCREVUS
University Nice Hospital, ROCHE
progressive multiple sclerosis, progressive multiple sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
PRECEPT, NCT04175834: Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab

Completed
3
19
US
cetrizine, Active comparator, diphenhydramine, Other
Providence Health & Services, Genentech, Inc.
Multiple Sclerosis, Infusion Reaction
05/22
05/22
Ocarina II, NCT05232825 / 2020-005448-48: A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

Hourglass Jan 2023 - Dec 2023 : Data from Ocarina II trial for multiple sclerosis
Hourglass Apr 2022 - Jul 2022 : First patient in of P3 Ocarina II trial for multiple sclerosis
Active, not recruiting
3
236
Europe, US, RoW
Ocrelizumab IV, RO4964913, Ocrelizumab SC, Methylprednisolone IV, Diphenhydramine IV, Dexamethasone given orally, Desloratadine given orally
Hoffmann-La Roche
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
04/25
04/25
NCT02688985 / 2015-004616-37: Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

Completed
3
131
Europe, Canada, US
Ocrelizumab, RO4964913, Lumbar Puncture, Methyloprednisolone, Antihistamine
Genentech, Inc.
Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
04/23
04/23
ENSEMBLE, NCT03085810 / 2016-002937-31: Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Completed
3
1239
Europe, Canada, US, RoW
Ocrelizumab
Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
04/23
04/23
RAM-MS, NCT03477500 / 2017-001362-25: Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS

Recruiting
3
100
Europe
Cyclophosphamide and ATG, Sendoxan, Alemtuzumab, Lemtrada, Cladribine Pill, Mavenclad, Ocrelizumab, Ocrevus
Haukeland University Hospital
Multiple Sclerosis
03/24
03/26
NCT03691077: Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714

Recruiting
3
51
Europe
Ocrelizumab
Assistance Publique - Hôpitaux de Paris, Roche Pharma AG, Institut du Cerveau et de la Moelle épinière
Multiple Sclerosis, Relapse, Primary Progressive Multiple Sclerosis
05/24
09/24
NCT03599245 / 2017-004886-29: This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Active, not recruiting
3
1500
Europe, Canada, RoW
Ocrelizumab
Hoffmann-La Roche
Multiple Sclerosis
02/25
09/25
NCT04544436 / 2020-000893-69: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Active, not recruiting
3
864
Europe, Canada, US, RoW
Ocrelizumab, Ocrevus, Antihistamine, Non-Investigational Medicinal Product, Methylprednisolone, Non-Investigation Medicinal Product
Hoffmann-La Roche
Multiple Sclerosis
12/24
08/28
OVERLORD-MS, NCT04578639: Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease

Active, not recruiting
3
214
Europe
Rituximab, mabthera, Ocrelizumab, ocrevus
Haukeland University Hospital, University Hospital, Akershus, Oslo University Hospital, Helse Stavanger HF, St. Olavs Hospital, University Hospital of North Norway
Relapsing Remitting Multiple Sclerosis
05/25
05/25
Operetta 2, NCT05123703 / 2020-004128-41: A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis

Recruiting
3
171
Europe, Canada, US, RoW
Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo
Hoffmann-La Roche, PPD
Relapsing-Remitting Multiple Sclerosis
07/25
09/29
NCT04548999 / 2020-000894-26: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Active, not recruiting
3
769
Europe, Canada, US, RoW
Ocrelizumab, Ocrevus, Antihistamine, Non-Investigational Medicinal Product, Methylprednisolone
Hoffmann-La Roche
Multiple Sclerosis
04/25
03/29
DanNORMS, NCT04688788: Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

Active, not recruiting
3
600
Europe
Rituximab, Ruxience, Rixathon® or other biosimilar rituximab, Ocrelizumab, Ocrevus, Fexofenadine, Paracetamol, Methylprednisolone
Rigshospitalet, Denmark, Odense University Hospital, Aarhus University Hospital, Aalborg University Hospital, Herlev Hospital, Hillerod Hospital, Denmark, Kolding Sygehus, Gødstrup Hospital, Hvidovre University Hospital, Hospital of South West Jutland, Esbjerg, Denmark, GCP unit, Copenhagen University Hospital, GCP-unit at Aarhus University Hospital, Aarhus, Denmark, Hospital of Southern Jutland, Sønderborg, Denmark, Hospital of Central Denmark Region, Viborg, Denmark, Danske Regioner, Hospital of Southern Jutland, Aabenraa, Denmark, Sanquin Research & Blood Bank Divisions
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
05/26
05/28
OLERO, NCT05269004 / 2021-005746-15: A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Active, not recruiting
3
1300
Europe, Canada, US, RoW
Ocrelizumab
Hoffmann-La Roche
Multiple Sclerosis
12/29
12/29
CONSONANCE, NCT03523858 / 2017-001313-93: A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Active, not recruiting
3
927
Europe, Canada, US, RoW
Ocrelizumab
Hoffmann-La Roche
Progressive Multiple Sclerosis (PMS)
01/26
12/26
FENtrepid, NCT04544449 / 2019-003919-53: A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Calendar Jan 2025 - Dec 2025:  Data from FENtrepid trial for Primary progressive multiple sclerosis
Active, not recruiting
3
985
Europe, Canada, US, RoW
Fenebrutinib, Ocrelizumab, Placebo matched to ocrelizumab, Placebo matched to fenebrutinib
Hoffmann-La Roche
Multiple Sclerosis, Primary Progressive
01/26
12/26
CONSONANCE EXT, NCT05210621: LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB

Active, not recruiting
3
72
Europe
Ocrelizumab
Centre Hospitalier Universitaire de Nice
Multiple Sclerosis
02/26
02/29
BEAT-MS, NCT04047628: Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis

Recruiting
3
156
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Best Available Therapy (BAT), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), rituximab (Rituxan®), cladribine (Mavenclad®), ofatumumab (Kesimpta®), ublituximab (BRIUMVI™)
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Blood and Marrow Transplant Clinical Trials Network, PPD, Rho Federal Systems Division, Inc.
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
10/26
10/29
NCT05906992: A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Recruiting
3
512
Europe
CT-P53, Ocrelizumab, US-Ocrevus, EU-Ocrevus
Celltrion
Relapsing-remitting Multiple Sclerosis
02/27
01/29
Noisy Rebels, NCT05834855: Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

Recruiting
3
200
Europe
Rituximab, MabThera, Truxima, Ruxience, Rixathon
Amsterdam UMC, location VUmc, Stichting Treatmeds
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases
05/27
05/27
WINDOCRE, NCT05999604: Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

Recruiting
3
244
Europe
Ocrelizumab Injection [Ocrevus]
Fondation Ophtalmologique Adolphe de Rothschild
Multiple Sclerosis
11/27
11/27
O'HAND, NCT04035005 / 2018-001511-73: A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Calendar Jan 2025 - Dec 2025: Efficacy and safety data from O'HAND trial in treatment of patients with multiple sclerosis
Recruiting
3
1000
Europe, Canada, US, RoW
Ocrelizumab, Ocrevus, Placebo
Hoffmann-La Roche
Multiple Sclerosis, Primary Progressive
12/27
11/30
TRIO, NCT05758831: RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

Recruiting
3
386
Europe
Perfusion of treatment Rituximab, Perfusion of treatment Ocrelizumab
Rennes University Hospital
Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis
03/30
05/30
NCT04925557: Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

Completed
2/3
18
US
Mayzent, Ocrevus
State University of New York at Buffalo
Secondary-progressive Multiple Sclerosis
06/23
08/23
NCT00676715 / 2007-006338-32: A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Checkmark
Mar 2013 - Mar 2013: 
Checkmark AAN 2013
Jan 2013 - Jan 2013: AAN 2013
Checkmark Data AAN (MS)
More
Completed
2
220
Europe, Canada, US, RoW
Placebo, Ocrelizumab, RO4964913, Avonex, Interferon-beta-alpha1
Genentech, Inc., Roche Pharma AG
Multiple Sclerosis, Relapsing-Remitting
03/12
11/23
2019-003127-38: Research on the effect of add-on high dosage simvastatin treatment on progression in MS patients treated with ocrelizumab and natalizumab. Onderzoek naar het effect van het toevoegen van hoge dosis simvastatine op progressie van MS patiënten die behandeld worden met ocrelizumab en natalizumab.

Not yet recruiting
2
100
Europe
Simvastatin, Tablet
VUmc Neurology Department, Stichting MS Research
Multiple sclerosis Multiple sclerose, Multiple sclerosis Multiple sclerose, Diseases [C] - Nervous System Diseases [C10]
 
 
2019-001967-58: Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with Relapsing Multiple Sclerosis (RMS)

Not yet recruiting
2
220
Europe
Dapirolizumab Pegol, OCREVUS, BIIB133, Lyophilisate for solution for infusion, Concentrate for solution for infusion, Ocrevus
Biogen Idec Research Limited, Biogen Idec Research Limited
Relapsing Multiple Sclerosis, Relapsing Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
2016-001166-29: A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic stem cell transplantation (aHSCT) in high inflammatory multiple sclerosis (COAST) Eine randomisierte kontrollierte Studie zum Vergleich von Ocrelizumab oder Alemtuzumab mit autologer hämatopoetischer Stammzelltransplantation (aHSCT) bei hoch entzündlicher Multipler Sklerose (COAST)

Not yet recruiting
2
50
Europe
alemtuzumab, ocrelizumab, autologous hematopoietic stem cells, aHSC, Solution for infusion, Lemtrada, Ocrevus
University Medical Centre Hamburg-Eppendorf, Neovii Pharmaceuticals AG
relapsing-remitting multiple sclerosis schubförmig remittierende Multiple Sklerose, multiple sclerosis with relapses that are followed by periods of partial or complete recovery Multiple Sklerose, die in einzelnen Schüben verläuft, welche sich vollständig oder unvollständig zurückbilden, Diseases [C] - Immune System Diseases [C20]
 
 
2022-002654-95: No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis Nessuna evidenza di attività della malattia dopo trapianto autologo di cellule staminali ematopoietiche nella Sclerosi Multipla aggressiva

Not yet recruiting
2
90
Europe
OCREVUS, Kesimpta 20 mg soluzione iniettabile, TYSABRI, LEMTRADA, Non disponibile, Solution for injection, Powder for concentrate for solution for infusion, Powder and solvent for concentrate for solution for infusion, Concentrate for solution for infusion, Powder and solvent for solution for injection, Powder for solution for injection, OCREVUS, Kesimpta, TYSABRI, LEMTRADA
FONDAZIONE ITALIANA SCLEROSI MULTIPLA ONLUS, Fondazione Italiana Sclerosi Multipla
Relapsing Remitting Multiple Sclerosis Sclerosi multipla recidivante remittente, A type of MS where you have relapses (symptoms getting worse) followed by recovery (that's when it's “remitting”) Forma di Sclerosi Multipla nella quale in cui si hanno ricadute (sintomi che peggiorano) seguite da guarigione (le remissioni)., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04075266 / 2016-002667-34: A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

Active, not recruiting
2
36
Europe, US
Ocrelizumab
Hoffmann-La Roche
Multiple Sclerosis
10/23
12/29
OPA, NCT03971487: Ocrelizumab for Psychosis by Autoimmunity

Recruiting
1/2
40
US
Psychosis and cognitive assessments, Physical and neuro-cognitive evaluations, Safety labs and electrocardiogram, Ocrelizumab infusion
The Methodist Hospital Research Institute, Genentech, Inc.
Schizo-Affective Type of Psychosis, Schizophrenia
06/25
10/25
NCT03972306: A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

Active, not recruiting
1
134
US
Ocrelizumab, rHuPH20
Hoffmann-La Roche
Multiple Sclerosis (MS)
06/25
06/25
NCT02807285: Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

No Longer Available
N/A
US
Ocrelizumab, RO4964913
Genentech, Inc.
Multiple Sclerosis
 
 
HepB20, NCT04519710: Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies

Completed
N/A
60
Europe
o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
HBV
09/21
10/23
SEP-RR, NCT04838015: Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS

Recruiting
N/A
250
Europe
University Hospital, Strasbourg, France
Multiple Sclerosis
11/21
11/21
CPE, NCT05762003: Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

Completed
N/A
17478
RoW
interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
IMPULS Endowment Fund
Multiple Sclerosis
12/21
12/21
NCT04855617: Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

Completed
N/A
122
US
Ocrelizumab, OCREVUS
NYU Langone Health, Genentech, Inc.
Multiple Sclerosis
10/22
10/22
NCT04640818: Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy

Active, not recruiting
N/A
45
Europe
Cladribine Oral Tablet, Mavenclade, Rituximab, Mabthera, Rixathon, Ocrelizumab, Ocrevus
Claudio Gobbi, Merck AG Switzerland
Multiple Sclerosis
10/22
10/22
NCT03562975: Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus

Active, not recruiting
N/A
18
US
Ocrelizumab, Ocrevus
University of South Florida, Genentech, Inc.
Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases, Autoimmune Diseases, Immune System Diseases, Primary Progressive Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
02/23
12/23
NCT03396822: Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis

Completed
N/A
24
US
Gadoteridol
University of Maryland, Baltimore, Genentech, Inc.
Multiple Sclerosis
05/23
05/23
NCT04843774: Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)

Completed
N/A
64
US
SARS-COV-2 mRNA Vaccine
NYU Langone Health
Multiple Sclerosis
04/23
04/23
NCT05627271: The 'Wearing Off' Effect of DMT

Completed
N/A
39
Europe
ocrelizumab, Ocrevus, natalizumab, Tysabri, ofatumumab, Kesimpta
Novartis Pharmaceuticals
Multiple Sclerosis
04/23
04/23
NCT03873389: Ocrelizumab Effects on the Metabolome in MS

Completed
N/A
25
US
Ocrelizumab, Ocrevus
Johns Hopkins University, Genentech, Inc.
Multiple Sclerosis
06/23
12/23
NCT04459988: Mechanistic Study of Ocrevus

Completed
N/A
35
US
Ocrelizumab, Ocrevus
University of Michigan
Multiple Sclerosis
10/22
10/22
NCT05081700: A Systems Approach to Understanding Disease Processes in Multiple Sclerosis

Active, not recruiting
N/A
14
US
All patients in the study will be treated with ocrelizumab, OCREVUS
Providence Health & Services, Institute for Systems Biology, Genentech, Inc.
Multiple Sclerosis
12/24
12/24
NCT04874597: Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes With Suppressive Capacity in MS

Active, not recruiting
N/A
30
RoW
Ocrelizumab
Dr Recai Turkoglu, Health Sciences University Istanbul Haydarpaşa Numune Training and Research Hospital
Multiple Sclerosis
11/23
11/23
NCT04448977: Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI

Recruiting
N/A
60
US
Ocrevus
Kessler Foundation, Hackensack Meridian Health
Multiple Sclerosis, Relapsing-Remitting
12/24
12/24
ORATORIO-Cort, NCT05974839: Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ical)

Active, not recruiting
N/A
732
US
Ocrelizumab
State University of New York at Buffalo, Genentech, Inc.
Primary Progressive Multiple Sclerosis
06/24
09/25
ORATORIO-CP, NCT05974852: Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS

Active, not recruiting
N/A
732
US
Ocrelizumab
State University of New York at Buffalo, Genentech, Inc.
Primary Progressive Multiple Sclerosis
11/24
09/25
NCT05266469: Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf

Recruiting
N/A
240
RoW
Ofatumumab, Ocrelizumab
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/24
12/24
NCT06121349: WOE of Anti-CD20 Therapies

Recruiting
N/A
150
US
ocrelizumab, Ocrevus, ofatumumab, KESIMPTA
Novartis Pharmaceuticals
Multiple Sclerosis
02/25
02/25
NCT04458688: Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

Recruiting
N/A
80
US
Observation of Ocrelizumab as Treatment in RRMS Patients, Observing Ocrelizumab Use
Wayne State University
Multiple Sclerosis, Relapsing-Remitting
07/25
12/30
MuSicalE, NCT03593590: Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

Active, not recruiting
N/A
1710
Europe, RoW
Ocrelizumab, Ocrevus
Hoffmann-La Roche
Multiple Sclerosis
07/25
07/25
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Recruiting
N/A
900
US
Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy, Tysabri, Lemtrada, Ocrevus, Rituxan, Mavenclad, Kesimpta, Briumvi, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/25
08/25
NCT05688436: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
N/A
1178
US
Diroximel Fumarate, VUMERITY, BIIB098, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Tysabri, BG00002, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
Biogen
Multiple Sclerosis
01/31
01/31
NCT05131984: Ocrelizumab Access by Socio-Economic Status

Not yet recruiting
N/A
600
US
Ocrelizumab
Brigham and Women's Hospital, Genentech, Inc., Boston Medical Center
Multiple Sclerosis
07/22
10/22
NCT04902690: The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients

Not yet recruiting
N/A
21
NA
IRCCS National Neurological Institute "C. Mondino" Foundation
Multiple Sclerosis Relapse
07/24
07/24

Download Options